CN101903514B - 能与scurfin结合的肽及其应用 - Google Patents

能与scurfin结合的肽及其应用 Download PDF

Info

Publication number
CN101903514B
CN101903514B CN2008801217329A CN200880121732A CN101903514B CN 101903514 B CN101903514 B CN 101903514B CN 2008801217329 A CN2008801217329 A CN 2008801217329A CN 200880121732 A CN200880121732 A CN 200880121732A CN 101903514 B CN101903514 B CN 101903514B
Authority
CN
China
Prior art keywords
peptide
seq
phe
scurfin
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801217329A
Other languages
English (en)
Chinese (zh)
Other versions
CN101903514A (zh
Inventor
伊尼斯·诺丽亚·凯撒瑞斯拉贾尔
弗朗西斯科·博拉斯奎斯塔
帕布鲁·萨罗韦乌加里萨
赫苏斯·普列托巴尔图埃纳
胡安·何塞·拉萨尔特萨加斯蒂韦尔萨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Original Assignee
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto de Biomedicina CIMA SL filed Critical Proyecto de Biomedicina CIMA SL
Publication of CN101903514A publication Critical patent/CN101903514A/zh
Application granted granted Critical
Publication of CN101903514B publication Critical patent/CN101903514B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2008801217329A 2007-11-19 2008-11-14 能与scurfin结合的肽及其应用 Expired - Fee Related CN101903514B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200703052A ES2328776B1 (es) 2007-11-19 2007-11-19 Peptidos con capacidad para unirse a escurfina y aplicaciones.
ESP200703052 2007-11-19
PCT/ES2008/000716 WO2009065982A1 (es) 2007-11-19 2008-11-14 Péptidos con capacidad para unirse a escurfina y aplicaciones

Publications (2)

Publication Number Publication Date
CN101903514A CN101903514A (zh) 2010-12-01
CN101903514B true CN101903514B (zh) 2013-07-17

Family

ID=40409793

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801217329A Expired - Fee Related CN101903514B (zh) 2007-11-19 2008-11-14 能与scurfin结合的肽及其应用

Country Status (11)

Country Link
US (1) US8524860B2 (enExample)
EP (1) EP2223998B1 (enExample)
JP (1) JP5385910B2 (enExample)
CN (1) CN101903514B (enExample)
AU (1) AU2008327792B2 (enExample)
BR (1) BRPI0819311A2 (enExample)
CA (1) CA2706201A1 (enExample)
ES (1) ES2328776B1 (enExample)
MX (1) MX2010005520A (enExample)
RU (1) RU2502741C2 (enExample)
WO (1) WO2009065982A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
AU2010259986B2 (en) 2009-06-10 2015-04-02 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
EP3107552B1 (en) * 2014-02-21 2018-03-28 Cellectis Method for in situ inhibition of regulatory t cells
ES2665543B1 (es) * 2016-10-26 2019-02-12 Fundacion Para La Investig Medica Aplicada Péptidos de unión a FOXP3 y usos de los mismos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698015A (en) * 1995-05-19 1997-12-16 Nikko Company Conductor paste for plugging through-holes in ceramic circuit boards and a ceramic circuit board having this conductor paste
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
ATE495255T1 (de) * 1998-08-11 2011-01-15 Darwin Discovery Ltd Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs
WO2001059115A2 (en) * 2000-02-09 2001-08-16 Agensys, Inc. 83p5g4: a tissue specific protein highly expressed in prostate cancer
US20030191073A1 (en) * 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
JP4353701B2 (ja) * 2001-05-08 2009-10-28 ダーウィン モレキュラー コーポレイション Ｆｏｘｐ３蛋白質を用いた霊長類における免疫機能の調節方法
US20080085261A1 (en) * 2004-10-19 2008-04-10 Haynes Barton F Vaccine Adjuvant
WO2007084775A2 (en) * 2006-01-20 2007-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
柴晓菲;薛瑞;许林平;高全立;买玲;.单次小剂量环磷酰胺对小鼠CD4~+CD25~+Treg细胞及抗肿瘤免疫力的影响.《新乡医学院学报》.2008,全文. *

Also Published As

Publication number Publication date
EP2223998A1 (en) 2010-09-01
US8524860B2 (en) 2013-09-03
EP2223998B1 (en) 2015-05-13
AU2008327792B2 (en) 2014-04-24
JP5385910B2 (ja) 2014-01-08
MX2010005520A (es) 2010-09-28
RU2502741C2 (ru) 2013-12-27
US20100267623A1 (en) 2010-10-21
JP2011504108A (ja) 2011-02-03
ES2328776A1 (es) 2009-11-17
RU2010125199A (ru) 2011-12-27
ES2328776B1 (es) 2010-07-06
AU2008327792A1 (en) 2009-05-28
CA2706201A1 (en) 2009-05-28
CN101903514A (zh) 2010-12-01
BRPI0819311A2 (pt) 2015-06-16
WO2009065982A1 (es) 2009-05-28

Similar Documents

Publication Publication Date Title
RU2632462C2 (ru) Направленная на циклин a1 t-клеточная иммунотерапия рака
RU2682726C9 (ru) Вакцинная композиция против злокачественной опухоли
CN1756763B (zh) 二聚体化肽
CA3072009A1 (en) Crcx4 inhibitor peptides for the treatment of diseases
US20230321218A1 (en) Sars-cov2 coronavirus reconstituted rbm and uses thereof
CN101903514B (zh) 能与scurfin结合的肽及其应用
MX2010013688A (es) Peptidos del epitope mybl2 y vacunas que los contienen.
CA2301499A1 (en) T-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof
JPS63502106A (ja) 抗原とｔ４リンパ球との相互作用を阻害し得るペプチド及び該ペプチドから誘導された産生物及びそれらの使用
US10172925B2 (en) Uses of partial peptides of survivin and variations thereof
KR100943825B1 (ko) 면역 반응을 강화하는 방법과 조성물
CN116514913B (zh) 具有抗肿瘤活性的tnfr2靶向肽及其应用
HUP0104254A2 (hu) Ezrin szabályozó/kihajtogató peptidek
HUE026977T2 (en) Promiseness HER-2 / NEU CD4 T-cell epitopes
JP2025503500A (ja) セストリン－ｍａｐｋ複合体阻害剤
AU2021418202A1 (en) SARS-CoV-2 PROTEIN-DERIVED PEPTIDE AND VACCINE CONTAINING SAME

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130717

Termination date: 20151114

EXPY Termination of patent right or utility model